Related Experiment Video
Updated: Dec 7, 2025
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Utilization of Polymer-Lipid Hybrid Nanoparticles for Targeted Anti-Cancer Therapy
Ayeskanta Mohanty1, Saji Uthaman2, In-Kyu Park1
1Department of Biomedical Sciences, Chonnam National University Medical School, 264, Seoyang-ro, Jeollanam-do 58128, Korea.
Abstract:
Cancer represents one of the most dangerous diseases, with 1.8 million deaths worldwide. Despite remarkable advances in conventional therapies, these treatments are not effective to completely eradicate cancer. Nanotechnology offers potential cancer treatment based on formulations of several nanoparticles (NPs). Liposomes and polymeric nanoparticle are the most investigated and effective drug delivery systems (DDS) for cancer treatment. Liposomes represent potential DDS due to their distinct properties, including high-drug entrapment efficacy, biocompatibility, low cost, and scalability. However, their use is restricted by susceptibility to lipid peroxidation, instability, burst release of drugs, and the limited surface modification. Similarly, polymeric nanoparticles show several chemical modifications with polymers, good stability, and controlled release, but their drawbacks for biological applications include limited drug loading, polymer toxicity, and difficulties in scaling up. Therefore, polymeric nanoparticles and liposomes are combined to form polymer-lipid hybrid nanoparticles (PLHNPs), with the positive attributes of both components such as high biocompatibility and stability, improved drug payload, controlled drug release, longer circulation time, and superior in vivo efficacy. In this review, we have focused on the prominent strategies used to develop tumor targeting PLHNPs and discuss their advantages and unique properties contributing to an ideal DDS.
Insights
Polymer-lipid hybrid nanoparticles (PLHNPs) combine the benefits of liposomes and polymeric nanoparticles for improved cancer treatment. These advanced drug delivery systems offer enhanced stability, drug loading, and efficacy in targeting tumors.
Area of Science:
- Nanomedicine and Drug Delivery
- Oncology
- Materials Science
Background:
- Cancer remains a leading cause of mortality, with conventional therapies often failing to achieve complete eradication.
- Nanoparticles (NPs) offer promising avenues for cancer treatment through advanced drug delivery systems (DDS).
- Liposomes and polymeric nanoparticles are key DDS but possess limitations such as instability, toxicity, and scalability issues.
Purpose of the Study:
- To review strategies for developing polymer-lipid hybrid nanoparticles (PLHNPs) for tumor-targeted cancer therapy.
- To highlight the advantages and unique properties of PLHNPs as an ideal DDS.
- To explore the synergistic benefits of combining polymer and lipid components in nanoparticle design.
Main Methods:
- Review of prominent strategies for synthesizing and functionalizing polymer-lipid hybrid nanoparticles (PLHNPs).
- Analysis of the physicochemical properties and in vitro/in vivo performance of PLHNPs.
- Discussion on tumor-targeting mechanisms and their contribution to therapeutic efficacy.
Main Results:
- Polymer-lipid hybrid nanoparticles (PLHNPs) integrate the strengths of liposomes and polymeric nanoparticles, overcoming individual limitations.
- PLHNPs demonstrate enhanced biocompatibility, stability, drug payload capacity, and controlled drug release kinetics.
- These hybrid systems exhibit improved circulation time and superior in vivo efficacy in preclinical cancer models.
Conclusions:
- Polymer-lipid hybrid nanoparticles (PLHNPs) represent a significant advancement in developing effective and targeted cancer drug delivery systems.
- The combination of polymer and lipid components offers a versatile platform for optimizing DDS properties for cancer therapy.
- Further research into PLHNPs holds great potential for improving patient outcomes in cancer treatment.
